Evaluation of the safety and efficacy of m-beam and m-beac regimen for autologous hematopoietic stem-cell transplantation pretreatment due to the shortage supply of melphalan (the second report)

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-HPS-093
• By: MIYAGAWA, Keiko (Kameda Medical Center, Kamogawa, Chiba, Japan)
• Co-author(s): Keiko Miyagawa: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
  Yusuke Nakagawa: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
  Tatsuya Isezaki: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
  Koji Masuda: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
  Osamu Yasumuro: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
  Kosei Matsue: Department of Hematology, Kameda Medical Center, Chiba, Japan
  Ryokan Funakoshi: Department of Pharmacy, Kameda Medical Center, Chiba, Japan
  
• Abstract:

  Background

  Melphalan IV (Mel) distribution has been suspended globally due to manufacturing process difficulties occurring in November 2015. We have been using the combination of Ranimustine/Etoposide/Cytarabine/Cyclophosphamide (M-BEAC) as pretreatment for autologous stem-cell transplantation (ASCT) instead of..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login